Defective Trustee Substitution Goes to Capacity—Not Article III Standing—and May Be Cured by Waiver/Ratification 1. Introduction In UMB Bank, N.A. v. Bristol-Myers Squibb Company (2d Cir. Aug. 13,...
Fourth Circuit Reaffirms Plain-Error Review of Unpreserved Rule 11/32 Claims and Presumptive Reasonableness of Within-Guidelines Sentences in Anders Appeals 1. Introduction In United States v. John...
Reverse-Payment Antitrust Standing Requires Proof FDA Approval Would Have Occurred Earlier (Not Merely Could Have) Case: In re: Lipitor Antitrust Litigation (3d Cir. Aug. 13, 2026) (Not Precedential)...
§ 1983 Facial Challenges to Illinois Post-Conviction DNA Testing: Standing Against the Prosecutor and No Rooker-Feldman Bar 1. Introduction In Reginald Chapman v. Eileen O'Neill Burke (7th Cir. Aug....
United States v. Matos: The Second Circuit Adopts Hunter’s “Miscarriage of Justice” Exception to Appeal Waivers—But Holds Routine Guidelines Disputes Still Waived; Standing-Order Incorporation...
Ex Parte Buccal-Swab DNA Warrants: No Pre-Issuance Hearing Required, and Probable Cause Need Not Identify a Viable Comparison Sample 1. Introduction United States v. Leeper (2d Cir. Aug. 13, 2026)...
Fourth Circuit: Foreign-Market Prescription Drugs Are “Non-Genuine” Gray-Market Goods When Labeling/Regulatory Disclosures and Distribution Quality Controls Materially Differ; Contributory Lanham...
Illinois Reliance-Based Estoppel Limits Nonsignatory Arbitration: “Direct Benefits Estoppel” Rejected Absent Detrimental Reliance 1. Introduction Sunco International Inc. v. Jiangsu Sunco Boiler Co.,...
Rule 54’s 14-Day Deadline Bars Late Requests for Appellate Fees Absent an Express Court Order 1. Introduction In Merchant v. Merchant (5th Cir. Aug. 13, 2026) (per curiam) (not designated for...
FDCA Does Not Preclude Lanham Act Gray‑Market Drug Claims; Contributory Infringement Knowledge Requires No Prior Notice 1. Introduction Case: Gilead Sciences, Inc. v. ProAct, Inc. (consolidated...
Reverse-Payment Antitrust Standing Requires Proof the FDA Would Have Approved Earlier (Not Merely Could Have) Case: In re: Lipitor Antitrust Litigation (3d Cir. Aug. 13, 2026) (not precedential) Core...
Coram Nobis Relief Demands Diligence and an “Obvious” Miscarriage of Justice; Tailored Filing Restrictions Upheld Case: United States v. Moreno (10th Cir. Aug. 13, 2026) (Order and Judgment,...
Reverse-Payment Antitrust Standing Requires Proof the FDA “Would Have” Approved Earlier (Not Merely “May Have”) Case: In re: Lipitor Antitrust Litigation (3d Cir. Aug. 13, 2026) (Not Precedential)...
Stress Is Not an Adverse Employment Action: Post-Muldrow Identifiable-Term Harm and Unchanged Hostile-Environment Thresholds Under Title VII I. Introduction In Gersen Gabriel v. DSM Biomedical, Inc....
Reverse-Payment Standing Requires Proof the FDA Would Have Approved Earlier (Not Merely Could Have) I. Introduction In re: Lipitor Antitrust Litigation (3d Cir. Aug. 13, 2026) is a Hatch-Waxman...
Bathroom Denial During a Search-Warrant Detention Can Be an “Obvious” Fourth Amendment Unreasonable Seizure Case: Derek Antol v. Robert English, et al. (6th Cir. Aug. 13, 2026) | Panel: Clay, Moore...
Seventh Circuit: No Third-Party Beneficiary Status—and No Broker Notice Duty to Non-Insured Claimants—Absent Explicit Contractual Intent Case: Robert Ferguson v. Aon Risk Services Companies, Inc....
Changed-Country-Conditions Motions to Reopen Must Compare to Conditions at the Original Merits Hearing (Not Later Benchmarks) 1. Introduction Ala Rahim Yonan v. Todd Blanche (Sixth Circuit, Aug. 13,...
Non‑Signatory Enforcement of Delegation Clauses: Courts Decide; State Law Governs Equitable Estoppel Even Under FAA Chapter 2 Case: Taewoo Kim v. Jump Trading, LLC Court: United States Court of...
Federal-Officer Element Under 18 U.S.C. §§ 111/1114 Satisfied by Task-Force Deputization or “Assisting” Status Without MOU Formalities 1. Introduction In United States v. Gigena (10th Cir. Aug. 13,...